A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis Kavi J. Littlewood, Kyoko Higashi,

Slides:

Advertisements

Similar presentations

Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature.

Advertisements

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to- patient contact C.R. Hansen, T. Pressler, W. Ridderberg, H.K.

Treatment compliance in children and adults with Cystic Fibrosis

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.

Direct antimicrobial susceptibility testing method for analysis of sputum collected from patients with cystic fibrosis Mohamed Zebouh, Caroline Thomas,

Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients Yvonne C.W. Yau, Felix Ratjen, Elizabeth Tullis,

Felix Ratjen, Paul Koker, David E

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.

Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled.

Patrick A. Flume, John P. Clancy, George Z. Retsch-Bogart, D

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

John Widger, Sarath Ranganathan, Philip J. Robinson

The ease of breathing test tracks clinical changes in cystic fibrosis

Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia P.Ø. Jensen, C. Moser, A. Kharazmi,

Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis Malin Carlsson, Leif Eriksson, Tania Pressler, Ragnhild Kornfält,

Controlled clinical trials in cystic fibrosis — are we doing better?

Inhaled aztreonam lysine vs

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

Vitamin A and lung function in CF

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation.

Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis Donna Drury, Vijay Laxmi Grey, Guylaine Ferland, Caren Gundberg,

Aukje C. Bos, Kimberly M. Passé, Johan W. Mouton, Hettie M

A.H. Gifford Journal of Cystic Fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Tregony Simoneau, Gregory S. Sawicki, Carly E. Milliren, Henry A

Inhalation solutions — Which ones may be mixed

Physiologic endpoints for clinical studies for cystic fibrosis

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Valerie Waters, Eshetu G

Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis M. Wang, W. Ridderberg, C.R. Hansen, N. Høiby,

Felix Ratjen, Florian Brockhaus, Gerhild Angyalosi

Elliott C. Dasenbrook, Gregory S. Sawicki Journal of Cystic Fibrosis

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients Valerie Waters, Eshetu G. Atenafu, Annie.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis M.N. Hurley, A.H. Amin Ariff, C. Bertenshaw,

Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS Dorota Sands, Ewa Sapiejka, Grzegorz.

C. Van de Kerkhove, P. C. Goeminne, M. Kicinski, T. S. Nawrot, N

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis C. Calabrese, A. Tosco, P. Abete, V. Carnovale,

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

Felix Ratjen, Todd Durham, Tomas Navratil, Amy Schaberg, Frank J

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa C.E. Wainwright, A.L. Quittner, D.E.

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis Kavi J. Littlewood, Kyoko Higashi, Jeroen P. Jansen, Gorana Capkun-Niggli, Maria-Magdalena Balp, Gerd Doering, Harm A.W.M. Tiddens, Gerhild Angyalosi Journal of Cystic Fibrosis Volume 11, Issue 5, Pages 419-426 (September 2012) DOI: 10.1016/j.jcf.2012.03.010 Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Study selection flow diagram. *Oermann data was only available in a poster. Journal of Cystic Fibrosis 2012 11, 419-426DOI: (10.1016/j.jcf.2012.03.010) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 The base case network of evidence. The network of studies that was included in the base case analysis is shown. Lines between boxes indicate which treatments were compared directly in a randomised controlled trial (RCT). Numbers in brackets reveal references. Tobramycin inhalation powder capsule (TIP), tobramycin inhalation solution 300mg/5ml (TIS-T), tobramycin inhalation solution 300mg/4ml (TIS-B), colistimethate sodium (colistin), aztreonam lysine for inhalation (AZLI). Journal of Cystic Fibrosis 2012 11, 419-426DOI: (10.1016/j.jcf.2012.03.010) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Overview of network meta-analysis scenario results for change in lung function of different antibiotics versus placebo. Exposed subgroup network did not include placebo. Fixed effects model (FEM), random effects model (REM), exposure status (EXP), forced expiratory volume (FEV), covariate (Cov), percent change from baseline (%CFB), forced expiratory volume in 1second percentage (FEV1%), tobramycin inhalation powder capsule (TIP), tobramycin inhalation solution 300mg/5ml (TIS-T), tobramycin inhalation solution 300mg/4ml (TIS-B), colistimethate sodium (colistin), aztreonam lysine for inhalation (AZLI). Journal of Cystic Fibrosis 2012 11, 419-426DOI: (10.1016/j.jcf.2012.03.010) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 4 Overview of network meta-analysis scenario results for change in lung function of TIP versus alternative antibiotics. Fixed effects model (FEM), Random effects model (REM), exposure status (EXP), forced expiratory volume (FEV), covariate (Cov), percent change from baseline (%CFB), forced expiratory volume in 1second percentage (FEV1%), tobramycin inhalation powder capsule (TIP), tobramycin inhalation solution 300mg/5ml (TIS-T), tobramycin inhalation solution 300mg/4ml (TIS-B), colistimethate sodium (colistin), aztreonam lysine for inhalation (AZLI). Journal of Cystic Fibrosis 2012 11, 419-426DOI: (10.1016/j.jcf.2012.03.010) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 5 Overview of network meta-analysis scenario results for change in sputum density of TIP versus alternative antibiotics. Fixed effects model (FEM), random effects model (REM), exposure status (EXP), forced expiratory volume (FEV), covariate (Cov), percent change from baseline (%CFB), forced expiratory volume in 1second percentage (FEV1%), tobramycin inhalation powder capsule (TIP), tobramycin inhalation solution 300mg/5ml (TIS-T), tobramycin inhalation solution 300mg/4ml (TIS-B), colistimethate sodium (colistin), aztreonam lysine for inhalation (AZLI). Journal of Cystic Fibrosis 2012 11, 419-426DOI: (10.1016/j.jcf.2012.03.010) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions